论文信息 - Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors. - 字舞流文

Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.

M. Fang | You‐cai Zhu | Wenxian Wang | Chun-wei Xu | K. Du | Xing-liang Li | Hua-fei Chen

[1] G. Middleton,et al. Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy , 2018, Pathology & Oncology Research.

[2] Quan Zhang,et al. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer , 2017, Scientific Reports.

[3] M. Beasley,et al. Hepatoid adenocarcinoma of the lung: Review of a rare form of lung cancer. , 2016, Respiratory medicine.

[4] J. Bariwal,et al. Review on EGFR Inhibitors: Critical Updates. , 2016, Mini reviews in medicinal chemistry.

[5] A. Reiter,et al. Hepatoid Adenocarcinoma – Review of the Literature Illustrated by a Rare Case Originating in the Peritoneal Cavity , 2010, Oncology Research and Treatment.